Procurement Summary
Country: USA
Summary: NICHD Biological Testing Facility (BTF)
Deadline: 28 Aug 2025
Other Information
Notice Type: Tender
TOT Ref.No.: 124463502
Document Ref. No.: 75N94020D00003
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Description
THIS IS A NOTICE OF INTENT TO AWARD WITHOUT PROVIDING FOR FULL AND OPEN COMPETITION. THIS IS NOT A SOLICITATION OR A REQUEST FOR COMPETITIVE PROPOSALS.
The purpose of this announcement is for the Contraceptive Development Program (CDP), within the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, to issue a modification on a sole source basis, under the authority of 41 U.S.C. 253 (c)(1) as implemented by FAR6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements and FAR 6.301-1(a)(2)(ii) to extend the ordering period of the existing IDIQ contract with SRI International (SRI), entitled “NICHD Biological Testing Facility (BTF).”
The objective is to extend the ordering period to ensure continuation of mission critical research while the NICHD procurement team continues to pursue the re-competition of these services under a new full and open cost reimbursement contract.
The proposed twenty-seven (27) month extension of the ordering period is necessary to prevent a lapse in continuity of critical services essential to the NICHD BTF and Contraceptive Clinical Trials Network (CCTN). This will ensure uninterrupted support for the conduct, coordination, and regulatory compliance of ongoing preclinical Good Laboratory Practices (GLP) studies and Good Manufacturing Practices (GMP) of investigational products (IP), and clinical contraceptive studies, avoiding costly and mission-compromising delays that would arise from a transition to a new contractor at this stage. Specifically, this action is necessary to ensure SRI continues providing the preclinical and clinical services supporting ongoing CCTN Phase I-III contraceptive clinical trial activities under Good Clinical Practices guidelines. SRI will also continue providing ancillary services such as meeting coordination, GMP investigational product (IP) manufacture, rele...
Active Contract Opportunity
Notice ID : 75N94020D00003
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office: NATIONAL INSTITUTES OF HEALTH NICHD
General Information
Contract Opportunity Type: Presolicitation (Updated)
Updated Published Date: Aug 13, 2025 07:39 pm EDT
Original Published Date: Aug 13, 2025 07:30 pm EDT
Updated Response Date: Aug 28, 2025 02:00 pm EDT
Original Response Date: Aug 28, 2025 02:00 pm EDT
Inactive Policy: Manual
Updated Inactive Date: Aug 28, 2025
Original Inactive Date: Aug 28, 2025
Initiative: None
Classification
Original Set Aside:
Product Service Code: AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Place of Performance: NC 27705 USA
Documents
Tender Notice